A new JCO Clinical Cancer Informatics (JCO CCI) article highlights the challenges in and need for obtaining real-world evidence (RWE) for assessing the effectiveness of precision medicine therapies on areas such as survival, quality of life, costs, and health disparities. RWE can be difficult to obtain because of the ways in which data is entered into electronic health records; one proposed solution is the mCODE™ initiative.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
Four abstracts are being featured in the press program for the 2019 Quality Care Symposium, which takes place September 6–7 in San Diego.
ASCO is seeking medical institutions in low- and middle-income countries (LMIC) in the Asia-Pacific region to organize one or two live educational courses per year as part of the Society’s International Cancer Corps (ICC). The request for proposals (RFP) process is now open, and all proposals are due December 1.
ASCO, through its Center for Research and Analytics (CENTRA®), has issued a request for research ideas from its members for projects that ASCO could conduct to develop generalizable new knowledge for the oncology community. Of particular need are research ideas that align with the priorities documented in Clinical Cancer Advances 2019: ASCO’s Annual Report on Progress Against Cancer and ASCO’s Strategic Plan or policy priorities. All ideas must be submitted by September 30 using a brief survey.
ASCO submitted comments to the Centers for Medicare & Medicaid Services (CMS) in response to the agency’s Request for Information (RFI) on Patients over Paperwork. ASCO’s comments provide the society’s perspective on improving the delivery of cancer care in a way that is beneficial for people with cancer and oncology professionals.
ASCO submitted comments to the Centers for Medicare & Medicaid Services (CMS) in response to a proposed rule regarding Secure Electronic Prior Authorization for Medicare Part D. Under the proposal, clinicians would be able to complete prior authorizations for Part D prescriptions online and through a more streamlined process.
ASCO, CancerLinQ LLC and its technology collaborator Concerto HealthAI, and data from the practices that participate in the CancerLinQ® platform will be a part of the upcoming “8th Annual Blueprint for Breakthrough Forum—Validating Real-World Endpoints for an Evolving Regulatory Landscape” forum hosted by Friends of Cancer Research on September 18 in Washington, D.C.
New results from ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study demonstrate that single-agent palbociclib has no meaningful clinical activity in patients with CDKN2A mutated or deleted advanced pancreatic adenocarcinoma and cholangiocarcinoma.
On August 15, 2019, the Food and Drug Administration granted accelerated approval to entrectinib (ROZLYTREK™, Genentech Inc.) for adults and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy.
On August 16, 2019, the Food and Drug Administration approved fedratinib (INREBIC®, Impact Biomedicines, Inc.) for adults with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
On August 15, ASCO announced the three recipients of its CancerLinQ Discovery® Research Support Grant, each of whom will undertake research projects using data from CancerLinQ Discovery®, an offering of ASCO’s CancerLinQ® initiative that provides de-identified data from cancer patients to academic researchers, government agencies, and others in the oncology community to generate practical knowledge that will improve cancer care.
On August 9, ASCO submitted a comment letter to Alex M. Azar II, Secretary of Health and Human Services (HHS), regarding the proposed rule on Sec. 1557 of the Affordable Care Act (ACA)—Nondiscrimination in Health and Health Education Programs or Activities.
Applications are now open for grant funding for 10 oncology practices in rural or urban centers in the U.S. that primarily treat underserved populations to participate in ASCO’s Quality Oncology Practice Initiative (QOPI®) and Quality Training Program offerings for a three-year period. The generous grant for more than $600,000 has been provided by the Stavros Niarchos Foundation, and it will fund each practice’s training and participation.
The Centers for Medicare & Medicaid Services (CMS) released a new national coverage determination (NCD) announcing that Medicare will now cover Food and Drug Administration (FDA)-approved Chimeric Antigen Receptor T-cell (CAR T-cell) therapy for certain patients with cancer.
ASCO President Howard A. “Skip” Burris III, MD, FACP, FASCO, made a statement applauding the Centers for Medicare & Medicaid Services (CMS) for releasing a national coverage determination (NCD) on CAR T-cell therapy that provides consistent and predictable access to an innovative cancer treatment to Medicare beneficiaries nationwide.